492 related articles for article (PubMed ID: 35013790)
1. The MEK1/2-inhibitor ATR-002 efficiently blocks SARS-CoV-2 propagation and alleviates pro-inflammatory cytokine/chemokine responses.
Schreiber A; Viemann D; Schöning J; Schloer S; Mecate Zambrano A; Brunotte L; Faist A; Schöfbänker M; Hrincius E; Hoffmann H; Hoffmann M; Pöhlmann S; Rescher U; Planz O; Ludwig S
Cell Mol Life Sci; 2022 Jan; 79(1):65. PubMed ID: 35013790
[TBL] [Abstract][Full Text] [Related]
2. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.
Garcia G; Sharma A; Ramaiah A; Sen C; Purkayastha A; Kohn DB; Parcells MS; Beck S; Kim H; Bakowski MA; Kirkpatrick MG; Riva L; Wolff KC; Han B; Yuen C; Ulmert D; Purbey PK; Scumpia P; Beutler N; Rogers TF; Chatterjee AK; Gabriel G; Bartenschlager R; Gomperts B; Svendsen CN; Betz UAK; Damoiseaux RD; Arumugaswami V
Cell Rep; 2021 Apr; 35(1):108940. PubMed ID: 33784499
[TBL] [Abstract][Full Text] [Related]
3. Antiviral efficacy against influenza virus and pharmacokinetic analysis of a novel MEK-inhibitor, ATR-002, in cell culture and in the mouse model.
Laure M; Hamza H; Koch-Heier J; Quernheim M; Müller C; Schreiber A; Müller G; Pleschka S; Ludwig S; Planz O
Antiviral Res; 2020 Jun; 178():104806. PubMed ID: 32304723
[TBL] [Abstract][Full Text] [Related]
4. Resveratrol and Pterostilbene Inhibit SARS-CoV-2 Replication in Air-Liquid Interface Cultured Human Primary Bronchial Epithelial Cells.
Ter Ellen BM; Dinesh Kumar N; Bouma EM; Troost B; van de Pol DPI; van der Ende-Metselaar HH; Apperloo L; van Gosliga D; van den Berge M; Nawijn MC; van der Voort PHJ; Moser J; Rodenhuis-Zybert IA; Smit JM
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372541
[TBL] [Abstract][Full Text] [Related]
5. Aprotinin Inhibits SARS-CoV-2 Replication.
Bojkova D; Bechtel M; McLaughlin KM; McGreig JE; Klann K; Bellinghausen C; Rohde G; Jonigk D; Braubach P; Ciesek S; Münch C; Wass MN; Michaelis M; Cinatl J
Cells; 2020 Oct; 9(11):. PubMed ID: 33143316
[TBL] [Abstract][Full Text] [Related]
6. Morphological cell profiling of SARS-CoV-2 infection identifies drug repurposing candidates for COVID-19.
Mirabelli C; Wotring JW; Zhang CJ; McCarty SM; Fursmidt R; Pretto CD; Qiao Y; Zhang Y; Frum T; Kadambi NS; Amin AT; O'Meara TR; Spence JR; Huang J; Alysandratos KD; Kotton DN; Handelman SK; Wobus CE; Weatherwax KJ; Mashour GA; O'Meara MJ; Chinnaiyan AM; Sexton JZ
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34413211
[TBL] [Abstract][Full Text] [Related]
7. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
[TBL] [Abstract][Full Text] [Related]
8. Influenza A virus replication has a stronger dependency on Raf/MEK/ERK signaling pathway activity than SARS-CoV-2.
Hoffmann H; Ebensperger M; Schönsiegel A; Hamza H; Koch-Heier J; Schreiber A; Ludwig S; Schindler M; Planz O
Front Cell Infect Microbiol; 2023; 13():1264983. PubMed ID: 37965261
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of MEK signaling prevents SARS-CoV2-induced lung damage and improves the survival of infected mice.
Xie J; Klemsz MJ; Kacena MA; Sandusky G; Zhang X; Kaplan MH
J Med Virol; 2022 Dec; 94(12):6097-6102. PubMed ID: 36030555
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of host cell serine protease inhibitor MM3122 against SARS-CoV-2 for treatment and prevention of COVID-19.
Boon ACM; Bricker TL; Fritch EJ; Leist SR; Gully K; Baric RS; Graham RL; Troan BV; Mahoney M; Janetka JW
J Virol; 2024 May; 98(5):e0190323. PubMed ID: 38593045
[TBL] [Abstract][Full Text] [Related]
11. Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production.
Fintelman-Rodrigues N; Sacramento CQ; Ribeiro Lima C; Souza da Silva F; Ferreira AC; Mattos M; de Freitas CS; Cardoso Soares V; da Silva Gomes Dias S; Temerozo JR; Miranda MD; Matos AR; Bozza FA; Carels N; Alves CR; Siqueira MM; Bozza PT; Souza TML
Antimicrob Agents Chemother; 2020 Sep; 64(10):. PubMed ID: 32759267
[TBL] [Abstract][Full Text] [Related]
12. Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Lim YS; Nguyen LP; Lee GH; Lee SG; Lyoo KS; Kim B; Hwang SB
Mol Cells; 2021 Sep; 44(9):688-695. PubMed ID: 34518443
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a novel mitogen-activated protein kinase kinase 1/2 inhibitor with a unique mechanism of action for cancer therapy.
Daouti S; Wang H; Li WH; Higgins B; Kolinsky K; Packman K; Specian A; Kong N; Huby N; Wen Y; Xiang Q; Podlaski FJ; He Y; Fotouhi N; Heimbrook D; Niu H
Cancer Res; 2009 Mar; 69(5):1924-32. PubMed ID: 19244124
[TBL] [Abstract][Full Text] [Related]
14. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
[TBL] [Abstract][Full Text] [Related]
15. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
Terrier O; Dilly S; Pizzorno A; Chalupska D; Humpolickova J; Bouřa E; Berenbaum F; Quideau S; Lina B; Fève B; Adnet F; Sabbah M; Rosa-Calatrava M; Maréchal V; Henri J; Slama-Schwok A
Molecules; 2021 Apr; 26(9):. PubMed ID: 33946802
[TBL] [Abstract][Full Text] [Related]
16. Saururus chinensis (Lour.) Baill blocks enterovirus 71 infection by hijacking MEK1-ERK signaling pathway.
Wang C; Wang P; Chen X; Wang W; Jin Y
Antiviral Res; 2015 Jul; 119():47-56. PubMed ID: 25912818
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 and the Possible Role of Raf/MEK/ERK Pathway in Viral Survival: Is This a Potential Therapeutic Strategy for COVID-19?
Ghasemnejad-Berenji M; Pashapour S
Pharmacology; 2021; 106(1-2):119-122. PubMed ID: 33011728
[No Abstract] [Full Text] [Related]
18. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
19. Synergistic Block of SARS-CoV-2 Infection by Combined Drug Inhibition of the Host Entry Factors PIKfyve Kinase and TMPRSS2 Protease.
Kreutzberger AJB; Sanyal A; Ojha R; Pyle JD; Vapalahti O; Balistreri G; Kirchhausen T
J Virol; 2021 Oct; 95(21):e0097521. PubMed ID: 34406858
[TBL] [Abstract][Full Text] [Related]
20. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
